
|Articles|July 28, 2022
Daily Medication Pearl: Argatroban Injection
Author(s)Saro Arakelians, PharmD
Argatroban is indicated for thrombosis in adult patients with heparin-induced thrombocytopenia and as an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention.
Advertisement
Medication Pearl of the Day: Argatroban Injection
Indication: Argatroban is a direct thrombin inhibitor indicated for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) and as an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention.
Insight:
- Dosing: Argatroban 125 mg in 125 mL aqueous sodium chloride solution (1 mg/mL) is intended for administration to adult patients.
- Dosage forms: Argatroban Injection is supplied as a single-use vial containing 125 mg argatroban in 125 mL aqueous sodium chloride solution.
- Adverse events: In HIT patients, the most common (> 5%) adverse reactions were dyspnea, hypotension, fever, diarrhea, sepsis, and cardiac arrest.
- Mechanism of action: Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5


























